Types of SPMs observed
| . | TT2 − T . | TT2 + T . | TT3A . | TT3B . | Total . |
|---|---|---|---|---|---|
| Total patients enrolled | 345 | 323 | 303 | 177 | 1148 |
| Total person-years | 2164 | 2135 | 1521 | 577 | 6397 |
| Solid-tissue SPMs | 13 | 10 | 11 | 2 | 36 |
| ALL | 0 | 0 | 1 | 0 | 1 |
| AML | 3 | 0 | 3 | 0 | 6 |
| NHL | 0 | 1 | 2 | 0 | 3 |
| MDS | 10 | 9 | 5 | 2 | 26 |
| Hematological SPMs | 11 | 18 | 7 | 1 | 37 |
| Bladder cancer | 1 | 1 | 1 | 0 | 3 |
| Breast cancer | 2 | 3 | 1 | 0 | 6 |
| Colon cancer | 0 | 2 | 0 | 1 | 3 |
| Lung cancer | 0 | 1 | 0 | 0 | 1 |
| Nonmelanoma cancer | 4 | 2 | 2 | 0 | 8 |
| Prostate cancer | 2 | 5 | 2 | 0 | 9 |
| Renal cancer | 0 | 2 | 1 | 0 | 3 |
| Thyroid cancer | 2 | 2 | 0 | 0 | 4 |
| Total | 24 | 28 | 18 | 3 | 73 |
| . | TT2 − T . | TT2 + T . | TT3A . | TT3B . | Total . |
|---|---|---|---|---|---|
| Total patients enrolled | 345 | 323 | 303 | 177 | 1148 |
| Total person-years | 2164 | 2135 | 1521 | 577 | 6397 |
| Solid-tissue SPMs | 13 | 10 | 11 | 2 | 36 |
| ALL | 0 | 0 | 1 | 0 | 1 |
| AML | 3 | 0 | 3 | 0 | 6 |
| NHL | 0 | 1 | 2 | 0 | 3 |
| MDS | 10 | 9 | 5 | 2 | 26 |
| Hematological SPMs | 11 | 18 | 7 | 1 | 37 |
| Bladder cancer | 1 | 1 | 1 | 0 | 3 |
| Breast cancer | 2 | 3 | 1 | 0 | 6 |
| Colon cancer | 0 | 2 | 0 | 1 | 3 |
| Lung cancer | 0 | 1 | 0 | 0 | 1 |
| Nonmelanoma cancer | 4 | 2 | 2 | 0 | 8 |
| Prostate cancer | 2 | 5 | 2 | 0 | 9 |
| Renal cancer | 0 | 2 | 1 | 0 | 3 |
| Thyroid cancer | 2 | 2 | 0 | 0 | 4 |
| Total | 24 | 28 | 18 | 3 | 73 |
Note that these frequencies should not be used as a means to assess by-protocol differences due to large differences in follow-up. For a by-protocol comparison, see Figures 2 through 4.
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; and MDS, myelodysplastic syndrome.